Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3- (trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 828-835

  Goda, Rika ^a   Nagai, Daichi ^a   Akiyama, Yuji ^a,b   Nishikawa, Kiyohiro ^a   Ikemoto, Isao ^b   Aizawa, Yoshio ^a,b   Nagata, Kiyoshi ^c   Yamazoe, Yasushi ^c  

^a NIPPON KAYAKU CO LTD   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYFLUTAMIDE; BIS(4 NITROPHENYL) PHOSPHATE; CARBOXYLESTERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ELLIPTICINE; ENZYME INHIBITOR; FLUTAMIDE; GLUCURONIDE; MICONAZOLE; N [4 NITRO 3 (TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE; RECOMBINANT CYTOCHROME P450; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DYSFUNCTION; LIVER MICROSOME; LIVER MICROSOME METABOLISM; LIVER TOXICITY; MALE; METABOLIC CLEARANCE RATE; METABOLIC RATE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN VARIANT; URINALYSIS; URINARY EXCRETION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUTAMIDE; HUMANS; INDICATORS AND REAGENTS; MALE; MICROSOMES, LIVER; NADP; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33645826544     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008623     Document Type: Article

References (27)

1. Aizawa Y, Ikemoto I, Kishimoto K, Wada T, Yamazaki H, Ohishi Y, Kiyota H, Furuta N, Suzuki H, and Ueda M (2003) Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol Cell Biochem 252:149-156.
2. Asakawa N and Yamashita K (1995) Studies on the metabolic fate of flutamide. Antibiot Chemother 11:1418-1427.
3. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D, et al. (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366-372.
4. Brogden RN and Chrisp P (1991) Flutamide a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer. Drugs Aging 1:104-115.
5. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962.
6. Garner RC and Nutman CA (1977) Testing of some azo dyes and their reduction products for mutagenicity using Salmonella typhimurium TA1538. Mutat Res 44:9-19.
7. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, and Labrie F (1992) Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92:465-470.
8. Kato R and Yamazoe Y (1994) Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metab Rev 26:413-430.
9. Matsuzaki Y, Doi M, Nagai D, Ichimura E, Goda R, Asakawa N, Tomura A, and Nishikawa K (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol, in press.
10. Matsuzaki Y and Nishikawa K (2003) Therapeutic options for drug induced liver injury: the efficacy of UDCA based on EBM. Nippon Shokakibyo Gakkai Zasshi 100:659-666.
11. Nakagawa Y, Koyama M, and Matsumoto M (1999) Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 45:821-826.
12. Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, Yoshida K, Ichinei M, Yamashita T, and Hirao Y (2002) Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 5:128-131.
13. Prostate Cancer Trialists' Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355:1491-1498.
14. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin J, Nakamura T, Nishiguchi K, Okamura N, and Okumura K (2005) Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities and its comparison with azole antifungal drugs. J Pharm Pharmacol 57:759-764.
15. Sanwald P, Blankson EA, Dulery BD, Schoun J, Huebert ND, and Dow J (1995) Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites. J Chromatogr B Biomed Appl 672:207-215.
16. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, and Bennett CL (2001) Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57:727-732.
17. Schulz M, Schmoldt A, Donn F, and Becker H (1988) The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 34:633-636.
18. Shet MS, McPhaul M, Fisher CW, Stallings NR, and Estabrook RW (1997) Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 25:1298-1303.
19. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
20. Slatter JG, Su P, Sams JP, Schaaf LJ, and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164.
21. Spain JC (1995) Biodegradation of nitroaromatic compounds. Annu Rev Microbiol 49:523-555.
22. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
23. Wada T, Ueda M, Abe K, Kobari T, Yamazaki H, Nakata J, Ikemoto I, Ohishi Y, and Aizawa Y (1999) Risk factor of liver disorders caused by flutamide - statistical analysis using multivariate logistic regression analysis. Acta Urol Jpn 45:521-526.
24. Watanabe N, Goda R, Irie T, and Yamashita K (2001) In vitro effects of fluoroquinolone anti-bacterial agents on flutamide metabolism in human liver microsomes. Jpn J Clin Pharmacol Ther 32:65-71.
25. Yamaguchi A, Ozono S, Kitauchi T, Nakanou I, Torimoto K, Fujimoto K, and Hirano Y (2001) Study of flutamide-induced liver disorders. Nishinihon J Urol 63:469-471.
26. Yamazoe Y, Abu-Zeid M, Yamauchi K, and Kato R (1988) Metabolic activation of pyrolysate arylamines by human liver microsomes; possible involvement of a P-448-H type cytochrome P-450. Jpn J Cancer Res 79:1159-1167.
27. Zimmerman HJ (1999) Drug-induced liver disease, in Disease of the Liver (Schiff ER, Sorrell MF, and Maddrey WC eds) pp 973-1064, Lippincott-Raven, Philadelphia.